Literature DB >> 19051065

Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Silvia Bucciarelli1, Doruk Erkan, Gerard Espinosa, Ricard Cervera.   

Abstract

The "catastrophic" variant of the antiphospholipid syndrome (APS) is characterized by multiple vascular occlusive events, usually affecting small vessels and developing over a short period of time. Although patients with catastrophic APS represent less than 1% of all patients with APS, they are usually in a life-threatening situation with a 50% mortality rate. The purpose of this paper is to review the treatment strategies and prognostic factors in patients with catastrophic APS. A detailed description of the clinical and laboratory features of the syndrome can be found in the other articles of this issue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051065     DOI: 10.1007/s12016-008-8107-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  36 in total

1.  Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years.

Authors:  C M Neuwelt; D I Daikh; J A Linfoot; D A Pfister; R G Young; R L Webb; S S London; R A Asherson
Journal:  Arthritis Rheum       Date:  1997-08

2.  Relapsing catastrophic antiphospholipid syndrome: report of three cases.

Authors:  Ronald A Asherson; Gerard Espinosa; Solomon Menahem; Janet Yinh; Silvia Bucciarelli; Xavier Bosch; Ricard Cervera
Journal:  Semin Arthritis Rheum       Date:  2007-10-30       Impact factor: 5.532

3.  Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity.

Authors:  Pier Luigi Meroni
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

Review 4.  Lessons from the "Euro-Phospholipid" project.

Authors:  Ricard Cervera
Journal:  Autoimmun Rev       Date:  2007-12-03       Impact factor: 9.754

Review 5.  The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome.

Authors:  Imad Uthman; Ali Shamseddine; Ali Taher
Journal:  Transfus Apher Sci       Date:  2005-08       Impact factor: 1.764

Review 6.  Antiphospholipid antibodies: lessons from the bench.

Authors:  Takao Koike; Miyuki Bohgaki; Olga Amengual; Tatsuya Atsumi
Journal:  J Autoimmun       Date:  2007-03-23       Impact factor: 7.094

7.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 8.  The management of the patient with unexpected autoantibody positivity.

Authors:  Marcello Bagnasco; Lidia Grassia; Giampaola Pesce
Journal:  Autoimmun Rev       Date:  2007-02-15       Impact factor: 9.754

9.  Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?

Authors:  Laura Andreoli; Francesca Pregnolato; Rufus W Burlingame; Flavio Allegri; Silvia Rizzini; Valentina Fanelli; Antonella Radice; Caterina Corace; Renato Alberto Sinico; Pier Luigi Meroni; Angela Tincani
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

Review 10.  Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

Authors:  Ilaria Cavazzana; Nebuloni Manuela; Cetin Irene; Acaia Barbara; Saino Sara; Borghi Maria Orietta; Tincani Angela; Tedesco Francesco; Meroni Pier Luigi
Journal:  J Autoimmun       Date:  2007-04-06       Impact factor: 7.094

View more
  8 in total

1.  Catastrophic antiphospholipid antibody syndrome as a first manifestation of primary antiphospholipid antibody syndrome in a middle-aged man.

Authors:  Nazrul Hassan Jafry; Muhammed Mubarak; Ejaz Ahmed; Fazal Akhtar
Journal:  CEN Case Rep       Date:  2020-01-27

Review 2.  Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis.

Authors:  Amelia Ruffatti; Antonia Calligaro; Carmelo S Lacognata; Anna D'Odorico; Anna Colpo; Fabrizio Cardin; Fiorella Calabrese
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

Review 3.  Use of rituximab in the antiphospholipid syndrome.

Authors:  Deepak Kumar; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 4.  Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome.

Authors:  Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

5.  Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report.

Authors:  Chiao-Zhu Li; Chiao-Ching Li; Chih-Chuan Hsieh; Meng-Chi Lin; Dueng-Yuan Hueng; Feng-Chen Liu; Yuan-Hao Chen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement.

Authors:  Aleksandra Rymarz; Stanisław Niemczyk
Journal:  BMC Nephrol       Date:  2018-06-08       Impact factor: 2.388

7.  Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome?

Authors:  Rafal Fudala; Agnieszka Krupa; Dorota Stankowska; Timothy C Allen; Anna K Kurdowska
Journal:  Clin Sci (Lond)       Date:  2010-01-26       Impact factor: 6.124

8.  The flare up of catastrophic antiphospholipid syndrome: a report of an immunosuppressive withdrawal-induced case.

Authors:  Sayyed Gholamreza Mortazavimoghaddam
Journal:  Iran J Med Sci       Date:  2011-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.